Completed PHASE1 INTERVENTIONAL NCT00557583

Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults

A Randomized, Double-blinded, Placebo-controlled, Sequential, Single Ascending Dose Evaluation of the Safety and Pharmacokinetics of VBY-376 in Healthy Adults

Sponsor: Virobay Inc.

Conditions Chronic Hepatitis C Infection

Interventions VBY 376

Updated 6 times since 2017 Last updated: Dec 27, 2013 Started: Nov 30, 2007 Primary completion: Feb 29, 2008 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Chronic Hepatitis C Infection and is currently completed. Virobay Inc. leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Virobay Inc.

Data source: Virobay Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States